Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD)’s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $14.36 and last traded at $14.16, with a volume of 298,223 shares changing hands. The stock had previously closed at $14.07.

Several brokerages have commented on IRWD. Cowen and Company reissued a “buy” rating on shares of Ironwood Pharmaceuticals in a research report on Sunday, April 17th. Morgan Stanley reissued a “hold” rating on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 26th. Wedbush reissued a “neutral” rating and set a $10.00 price objective (up previously from $9.00) on shares of Ironwood Pharmaceuticals in a research report on Thursday, April 28th. JP Morgan Cazenove reissued an “overweight” rating and set a $15.00 price objective on shares of Ironwood Pharmaceuticals in a research report on Thursday, April 28th. Finally, Mizuho reissued a “buy” rating and set a $15.00 price objective on shares of Ironwood Pharmaceuticals in a research report on Thursday, April 28th. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Ironwood Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $14.67.

The company has a 50 day moving average of $13.06 and a 200-day moving average of $11.07. The firm’s market capitalization is $2.05 billion.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Monday, May 9th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. During the same quarter in the prior year, the company earned ($0.24) EPS. The firm earned $66 million during the quarter, compared to analyst estimates of $52.97 million. The business’s revenue was up 128.4% on a year-over-year basis. Analysts predict that Ironwood Pharmaceuticals Inc. will post ($0.58) earnings per share for the current fiscal year.

In related news, Director Lawrence S. Olanoff sold 2,200 shares of the company’s stock in a transaction that occurred on Friday, June 3rd. The stock was sold at an average price of $12.92, for a total value of $28,424.00. Following the sale, the director now owns 32,505 shares in the company, valued at approximately $419,964.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Halley E. Gilbert sold 20,275 shares of the company’s stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $12.19, for a total value of $247,152.25. Following the completion of the sale, the insider now owns 5,865 shares in the company, valued at approximately $71,494.35. The disclosure for this sale can be found here.

Other large investors have recently added to or reduced their stakes in the company. Janus Capital Management boosted its stake in Ironwood Pharmaceuticals by 2.0% in the third quarter. Janus Capital Management now owns 15,889,356 shares of the company’s stock worth $165,569,000 after buying an additional 309,541 shares in the last quarter. Rhumbline Advisers boosted its stake in Ironwood Pharmaceuticals by 11.6% in the fourth quarter. Rhumbline Advisers now owns 123,715 shares of the company’s stock worth $1,434,000 after buying an additional 12,840 shares in the last quarter. ProShare Advisors LLC boosted its stake in Ironwood Pharmaceuticals by 10.9% in the fourth quarter. ProShare Advisors LLC now owns 120,454 shares of the company’s stock worth $1,396,000 after buying an additional 11,825 shares in the last quarter. California State Teachers Retirement System boosted its stake in Ironwood Pharmaceuticals by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 233,338 shares of the company’s stock worth $2,704,000 after buying an additional 3,727 shares in the last quarter. Finally, Nationwide Fund Advisors boosted its stake in Ironwood Pharmaceuticals by 1.7% in the fourth quarter. Nationwide Fund Advisors now owns 112,315 shares of the company’s stock worth $1,302,000 after buying an additional 1,851 shares in the last quarter.

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.